SCHEMBL4771872

SCHEMBL4771872

C[C@@H](Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1)[C@H](O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.45
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP2 O95551 1/20 0.41
NSD2 O96028 1/20 0.41
G6PD P11413 1/20 0.41
CDC25B P30305 1/20 0.41
DUSP3 P51452 1/20 0.41
HKDC1 Q2TB90 1/20 0.41
LDHA P00338 1/20 0.41
LDHB P07195 1/20 0.41
CYP19A1 P11511 1/20 0.40
ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239978 0.79 CYP1A2 (0.46) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4774839 0.78 DYRK1A (0.51) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4771477 0.78 CYP2D6 (0.46) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4773513 0.76 CYP2A6 (0.44) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4775017 0.76 CYP2A6 (0.44) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4773536 0.76 CYP2A6 (0.44) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4765936 0.76 CYP1A2 (0.41) CYP1A2NPC1TSHRRAB9AADORA3
SCHEMBL3962124 0.76 CYP2A6 (0.46) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4766345 0.76 CYP2A6 (0.46) CYP2A6CYP1A2CYP3A4CYP2C9NPC1
SCHEMBL4766379 0.76 CYP2A6 (0.46) CYP2A6CYP1A2CYP3A4CYP2C9NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed